Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Sales of Investments

Cash received from selling or redeeming investments.

Cardiff Oncology, Inc.NASDAQ: CRDF

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments dips below year-ago levels

Q1 FY2026 sales of investments of $15.83M fell 25.4% year over year, behind the +28.1% change in trailing-twelve-month sales of investments. Sequentially, it fell 9.4% from the prior quarter. Over 3 fiscal years it compounded at -17.5% a year.

Context

  • Sales of investments amounted to 12351.8% of revenue in FY2025, up 6880.2 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -25.4% toward the trailing-twelve-month pace of +28.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.83M-9.4% QoQ
Last fiscal yearDec 2025
$73.25M+96.0% YoY
LTMMar 2026
$67.84M+28.1% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.4%——
1 year+96.0%——
3-year CAGR-17.5%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
73.25M USD
Year-over-year change
+96.0%
4-year CAGR
+14.1%

Sales of Investments vs competitors

How CRDF compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +28.1% is the 3rd highest of 8, against a peer median of -54.2%.
  • Sales of investments amounts to 12922.7% of revenue for CRDF, versus a peer median of 844.1%.
CRDF Competitors
Sales of Investments for CRDF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$138.92M USD+29.2%+11.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 103.25M CHF-59.1%-11.6%—
PEPGPepGen Inc.LTM Mar 2026$82M USD-28.1%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$67.84M USD+28.1%-17.5%12922.7%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$59.86M USD-54.2%+48.2%3355.7%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$26.75M USD-65.8%+107.4%844.1%
IPHAInnate Pharma S.A.FY2025€13.51M EUR+40.9%+65.2%484.9%
FBRXForte Biosciences, Inc.LTM Mar 2026$0 USD-100.0%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding CRDF) —-54.2%+48.2%844.1%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Depreciation & Amortization451K236K398K404K904K
Deferred Income Tax1.32M0000
Stock-Based Compensation3.23M4.26M4.51M4.76M5.69M
Change in Working Capital(1.79M)(380K)6.57M3.17M2.18M
Accounts Receivables(215K)(236K)483K(484K)591K
Inventory00000
Accounts Payables719K1.35M2.83M2.99M2.2M
Other Working Capital(2.29M)(1.49M)3.25M671K(614K)
Other Non-Cash Items2.03M772K(921K)(598K)(848K)
Operating Cash Flow(23.04M)(33.82M)(30.89M)(37.69M)(37.92M)
Capital Expenditures(205K)(892K)(582K)(80K)(44K)
Acquisitions (Net)205K(114K)000
Purchases of Investments(174.39M)(91.23M)(70.08M)(23.56M)(71.12M)
Sales of Investments43.14M130.27M106.86M37.37M73.25M
Other Investing Activities(205K)114K00(744K)
Investing Cash Flow(131.45M)38.15M36.2M13.73M1.34M
Debt Repayment00000
Common Stock Issued34.19M75K053.41M2.58M
Common Stock Repurchased00000
Dividends Paid(24K)(414K)000
Other Financing Activities1.29M414K0373K0
Financing Cash Flow35.45M75K053.78M2.58M
Effect of Forex Changes00000
Net Change in Cash(119.04M)4.4M5.31M29.82M(34M)
Free Cash Flow(23.25M)(34.71M)(31.47M)(37.77M)(37.97M)

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.